ゼオマイン筋注用 50 単位
ゼオマイン筋注用 100 単位
ゼオマイン筋注用 200 単位

製造販売承認申請書添付資料

第 2 部（モジュール 2）

2.7　臨床概要
2.7.5　参考文献

帝人ファーマ株式会社

2.7.1　参考文献

1）Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57(4):555-65.
2）Eisele KH, Taylor HV. Dissociation of the 900kDa neurotoxin complex from C. botulinum under physiological conditions. Toxicon. 2008;51(1):10.
3）Draft Guidance for Industry, Assay Development for Immunogenicity Testing of Therapeutic Proteins. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 2009.
4）Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009, Committee for Medicinal Products for Human Use. 2011.
5）Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004 Jun;289(1-2):1-16.
6）Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008 Dec 15;48(5):1267-81.

2.7.2　参考文献

1）Dressler D, Hallett M. Immunological aspects of Botox®, Dysport® and Myobloc™/NeuroBloc®. Eur J Neurol. 2006;13Suppl 1:11-5.
2）Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics. 2010;4:325-32.
3）Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57(4):555-65.
4）Eisele KH, Taylor HV. Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions. Toxicon. 2008;51Suppl:10.
5）Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX®) in healthy volunteers. J Neural Transm. 2005;112(7):905-13.
6）Minor V. Ein neues Verfahren zu der klinischen Untersuchung der Schweißabsonderung. Dtsch Z Nervenheilkd. 1928;101(1):302-8.

2.7.3　参考文献

1）Ashworth B. Preliminary Trial of Carisoprodol in Multiple Sclerosis. Practitioner. 1964;192:540-2.
2）Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity.

Phys Ther. 1987;67(2):206-7.

3）Barnes M, Schnitzler A, Madeiros L, Aguilar M, Lehnert-Batar A, Minnasch P. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies - a randomized parallel-group study. Acta Neurol Scand. 2010;122(4):295-302.

4）Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies JM, Gordon MF, et al. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil. 2002;83(10):1349-54.

5）Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil. 1999;13(5):373-83.

6）Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46(5):1306-10.

7）Kanovsky P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009;32(5):259-65.

8）Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010;257:1330-7.

9）Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin. 2010;26(8):1983-92.

10）Simpson DM, Gracies JM, Graham K, Hallett M, Miyasaki J, Naumann M, et al. Assessment: Botulinum Neurotoxin for the Treatment of Spasticity (an evidence-based review). Neurology. 2009;73:737-8.

11）Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69(2):217-221.

12）Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 2001;71(2):193-9.

13）Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. J Neurol 2010;257 (7):1067-72.

14）Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, et al. Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke 2006;37(10):2567-72.

15）Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud 1988;10(2):61-3.

16）Platz T, Vuadens P, Eickhof C, Arnold P, Van Kaick S, Heise K. REPAS, a summary rating scale

for resistance to passive movement: item selection, reliability and validity. Disabil Rehabil. 2008;30(1):44-53.

17）Holden MK, Gill KM, Magliozzi MR. Gait assessment for neurologically impaired patients. Standards for outcome assessment. Phys Ther. 1986;66(10):1530-9.

18）Mehrholz J, Wagner K, Rutte K, Meissner D, Pohl M. Predictive validity and responsiveness of the functional ambulation category in hemiparetic patients after stroke. Arch Phys Med Rehabil. 2007;88(10):1314-9.

19）Rousseaux M, Compere S, Launay MJ, Kozlowski O. Variability and predictability of functional efficacy of botulinum toxin injection in leg spastic muscles. J Neurol Sci. 2005;232(1-2):51-7.

20）Turner-Stokes L, Williams H. Goal attainment scaling: a direct comparison of alternative rating methods. Clin Rehabil. 2010;24(1):66-73.

21）Poulain B, Popoff MR, Molgo J. How do the Botulinum Neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. The Botulinum J. 2008;1(1):14-87.

22）Minor V. Ein neues Verfahren zu der klinischen Untersuchung der Schweißabsonderung. Deutsch Z Nervenhlk 1928;101:302-8.

23）Lance JW. Symposium Synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity, disordered motor control. Miami: Symposia Specialists; 1980. p. 485-94.

24）Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve. 2005;31(5):552-71.

25）McGuire JR. Epidemiology of Spasticity in the Adult and Child. In: Elovic E, Brashear A, editors. Spasticity: Diagnosis and Management. 2nd ed: demos Medical; 2015. p. 5-15.

26）Ward AB, Aguilar M, De Beyl Z, Gedin S, Kanovsky P, Molteni F, et al. Use of botulinum toxin type A in management of adult spasticity - A European consensus statement. J Rehabil Med. 2003;35(2):98-9.

27）Elovic E, Zafonte RD. Spasticity Management in traumatic brain injury. Phys Med Rehabil State Art Rev. 2001;15(2):327-48.

28）Mayer NH. Spasticity and Other Signs of the Upper Motor Neuron Syndrome. In: Brashear A, Elovic E, editors. Spasticity : diagnosis and management. 2nd ed: demos Medical; 2016. p. 17-31.

29）Jankovic J. Botulinum Toxin - Therapeutic Clinical Practice and Science. In: Jankovic J, editor. Botulinum Toxin - Therapeutic Clinical Practice & Science. 1st, 2009 ed: Saunders Elsevier; 2009.

30）Wissel J, Muller J, Heinen F, Mall V, Sojer M, Ebersbach G, et al. Sicherheit und Verträglichkeit einer einmaligen Botulinum Toxin Typ A-Behandlung bei 204 Patienten mit Spastizität und lokalen assoziierten Störungen. Wien Klin Wochenschr. 1999;111(20):837-42.

31）Intiso D, Simone V, Rienzo FD, Iarossi A, Pazienza L, Santamato A, et al. High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury

and cerebral palsy. Nero Rehabilitation. 2014;34:515-522.

32）Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil Neural Repair. 2003;17(1):66-70.

33）Bergfeldt U, Borg K, Kullander K, Julin P. Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients. J Rehabil Med. 2006;38(3):166-71.

34）Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, et al. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology. 2017;89(22):2245-53.

35）Afssaps. Recommandations de Bonne Pratique, Traitements medicamenteux de la Spasticite. 2009.

36）Royal College of Physicians. Spasticity in adults: management using botulinum toxin. British Society of Rehabilitation Medicine. 2009:1-72.

37）Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:74-93.

38）Iaccarino MA, Bhatnagar S, Zafonte R. Management of Brain Injury Related Spasticity. In: Brashear A, Elovic E, editors. Spasticity : diagnosis and management. 2nd ed: demos Medical; 2015. p. 413-28.

39）Wein T, Esquenazi A, Jost WH, Ward AB, Pan G, Dimitrova R. OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial. PM R. 2018;10(7):693-703.

40）Dunne JW, Gracies JM, Hayes M, Zeman B, Singer BJ; Multicentre Study Group. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke. Clin Rehabil. 2012;26(9):787-97.

41）Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13-25.

42）Arimura K, Arimura Y, Takata Y, Nakamura T, Kaji R. Comparative electrophysiological study of response to botulinum toxin type B in Japanese and Caucasians. Mov Disord. 2008;23(2):240-5.

43）Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, et al. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia. J Neural Transm (Vienna). 2013;120(12):1699-707.

44）Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, et al. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm. J Neural Transm (Vienna). 2013;120(9):1345-53.

45）Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9(2):213-7.

46）Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences. Exp Neurol. 1997;147(1):96-102.
47）Dressler D, Bigalke H. Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol. 2004;52(3):132-5.
48）Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006;13 Suppl 1:11-5.
49）Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92(1):e48-e54.
50）Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm. 2013;120(2):275-90.

2.7.4　参考文献

1）Appelros P, Stegmayr B, Terént A. Sex differences in stroke epidemiology: a systematic review. Stroke. 2009;40(4):1082-90.
2）Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1-2):1-16.
3）Santos JI, Swensen P, Glasgow LA. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics. 1981;68(1):50-4.
4）Wang YC, Burr DH, Korthals GJ, Sugiyama H. Acute toxicity of aminoglycoside antibiotics as an aid in detecting botulism. Appl Environ Microbiol. 1984;48(5):951-5.
5）Yamada S, Kuno Y, Iwanaga H. Effects of aminoglycoside antibiotics on the neuromuscular junction: Part I. Int J Clin Pharmacol Ther Toxicol. 1986;24(3):130-8.
6）Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059-70.
7）Marchini C. Intranasal neostigmine therapy of botulinum toxin (BTX) treatment dysphagia. Clin Neuropharmacol. 1997;20(3):279-80.
8）Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, Weisman RS, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA. 2006;296(20):2476-9.
9）Reddihough D, Erasmus CE, Johnson H, McKellar GM, Jongerius PH. Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:109-21.

2.7.6　参考文献

1）Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M, et al. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin. 2010;26(8):1983-92.

2）Barnes M, Schnitzler A, Madeiros L, Aguilar M, Lehnert-Batar A, Minnasch P. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies - a randomized parallel-group study. Acta Neurol Scand. 2010;122(4):295-302.

3）Elovic E, Munin MC, Kanovsky P, Hanschmann A, Hiersemenzel R, Marciniak C. Results from a randomized, placebo-controlled, phase 3 study investigating the safety and efficacy of Xeomin in treating poststroke spasticity of the upper limb. Toxicon. 2015;93:S23.

4）Kanovsky P, Barnes M, Pulte I, Minnasch P, Grafe S. Efficacy of NT 201 (Botulinum Neurotoxin Type A, Free from Complexing Proteins) in the Treatment of Patients with Upper Limb Spasticity. Neurology. 2010;74(9).

5）Kanovsky P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, et al. Efficacy and Safety of Botulinum Neurotoxin NT 201 in Poststroke Upper Limb Spasticity. Clin Neuropharmacol. 2009;32(5):259-65.

6）Roggenkamper P, Hauschke D. Poster: IncobotulinumtoxinA demonstrated equal efficacy to onabotulinumtoxinA in the treatment of blepharospasm. Presented at the Toxins Congress in Miami Beach, 2012.

7）Merz Pharmaceuticals GmbH. Summary of Product Characteristics, XEOMIN 100 units powder for solution for injection. 2014.

8）Kanovsky P, Pulte I, Comes G, Grafe S. Repeated treatments with NT 201 (Xeomin®; Botulinum neurotoxin type A free from complexing proteins) are safe and effective for up to 89 weeks in upper limb post-stroke spasticity. J Neural Transm. 2010;117:1236.

9）Sheean G. Botulinum toxin should be first-line treatment for poststroke spasticity. J Neurol Neurosurg Psychiatry. 2009;80(4):359.

10）Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1691-8.

11）Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13-25.